Add Formweb to your mobile device
Search results for:
denosumab
denosumab
Brand names: Bomyntra, Bomyntra Prefilled Syringe, Conexxence Prefilled Syringe, Jubbonti Prefilled Syringe, Osenvelt, Prolia, Stoboclo Prefilled Syringe, Wyost, Xgeva
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLUTION, SUBCUTANEOUS | 60 mg/mL; 120 mg/1.7 mL; bbdz 60 mg/mL; bbdz 120 mg/1.7 mL; bmwo 60 mg/mL; bmwo 120 mg/1.7 mL; bnht 60 mg/mL; bnht 120 mg/1.7 mL | restricted |
Last updated: Oct. 15, 2025
- Black Box Warning: Severe Hypocalcemia in Patients with Advanced Kidney Disease and Severe Hypocalcemia and Mineral Metabolism Changes
- Therapeutic Interchange: Biosimilar and Reference Products Conversion List for Adults
- Restricted: denosumab is restricted to use in the Outpatient setting
Chemotherapy Chart
Medication
Reference Drug or Biosimilar
Formulary Status
Automatic Therapeutic Interchange
Inpatient1
Outpatient
*New Starts/New Authorizations Only*
Xgeva (denosumab)
Reference
Formulary, restricted to OP (preferred)
NFT approval is needed
Use Xgeva unless third party payer requires other denosumab product
Wyost (denosumab-bbdz)
Osenvelt (denosumab-bmwo)
Bomyntra (denosumab-bnht)
Xbryk (denosumab-dssb)
Biosimilars
Formulary, restricted to OP
(not preferred)
Interchange to Xgeva unless third party payer requires other denosumab product
Medication
Reference Drug or Biosimilar
Formulary Status
Automatic Therapeutic Interchange
Inpatient1
Outpatient
*New Starts/New Authorizations Only*
Prolia (denosumab)
Reference
Formulary, restricted to OP (preferred)
NFT approval is needed
Use Prolia unless third party payer requires other denosumab product
Jubbonti (denosumab-bbdz)
Stoboclo (denosumab-bmwo)
Conexxence (denosumab-bnht)
Ospomyv (denosumab-dssb)
Biosimilars
Formulary, restricted to OP
(not preferred)
Interchange to Prolia unless third party payer requires other denosumab product